SavedAdd your journal

Journals / Ege Tıp Dergisi / 2021 / Cilt: 60 - Sayı: Supplement

Rheumatoid arthritis treatment strategies: Switch or swap?

Romatoid artrit tedavi prensipleri: Neye geçiş yapalım?

Gonca Karabulut
Zeynep Özbalkan Aşlar
Pages
42–43
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Detailed studies should be planned for developing tailoring therapies.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Rheumatoid arthritis is the most common inflammatory disease in adults.
📊
Key Findings & Data:Modifications for treatment should be made until reaching the goals.
💡
Conclusion & Impact:Detailed studies should be planned for developing tailoring therapies.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Rheumatoid arthritis is the most common inflammatory disease in adults. Modifications for treatment should be made until reaching the goals. Detailed studies should be planned for developing tailoring therapies.

Özet

Romatoid artrit erişkinde en sık görülen inflamatuar artrittir. Remisyon veya düşük hastalık aktivitesi sağlanana kadar tedavi modifikasyonları yapılmalıdır. Gelecekte yapılacak daha kapsamlı çalışmalar ile bireyselleştirilmiş tedavilerin geliştirilmesi mümkün olabilecektir.

🔖

Cite This Article

Karabulut, G., Aşlar, Z. Ö. (2022). Rheumatoid arthritis treatment strategies: Switch or swap?. Ege Tıp Dergisi, Cilt: 60 - Sayı: Supplement, 42–43. https://ajindex.com/articles/496105

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (6)

  1. Smolen JS, Aletaha D, Bijlsma JW, et al. T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010; 69 (4): 631-7
  2. Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 2016; 75 (1): 3-15
  3. Smolen JS, Landewé R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017; 76 (6): 960-77
  4. Singh JA, Saag KG, Bridges SL Jr, et al. American College of Rheumatology. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res 2016; 68 (1): 1-25
  5. Upchurch KS, Kay J. Evolution of treatment for rheumatoid arthritis. Rheumatology (Oxford). 2012; 51 (Suppl 6): vi28-36
  6. Acosta-Herrera M, González-Serna D, Martín J. The potential role of genomic medicine in the therapeutic management of rheumatoid arthritis. J Clin Med 2019; 10; 8(6). pii: E826. doi: 10.3390/jcm8060826. Review.